Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels

Archives of Neurology

Volumn 69, Issue 3, 2012, Pages 394-397

  Criswell, Susan R ^a,c   Perlmutter, Joel S ^a,b,c   Crippin, Jeffrey S ^a   Videen, Tom O ^a,b,c   Moerlein, Stephen M ^b   Flores, Hubert P ^a   Birke, Angela M ^a   Racette, Brad A ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c American Parkinson Disease Association Advanced Center for Parkinson Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; DNA POLYMERASE; FUROSEMIDE; HEPATITIS B ANTIGEN; LAMIVUDINE; MANGANESE; PHYTOMENADIONE; POTASSIUM CHLORIDE; PROPRANOLOL; SPIRONOLACTONE; THIAMINE;

ADULT; ALCOHOL LIVER CIRRHOSIS; ALCOHOLISM; ARTICLE; ASCITES; BRADYKINESIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG ABUSE; END STAGE LIVER DISEASE; ESOPHAGUS VARICES; HEPATITIS B; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; MALE; MEDICAL HISTORY; MINI MENTAL STATE EXAMINATION; NEUROTOXICITY; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RIGIDITY; TREMOR;

CAUDATE NUCLEUS; CERULOPLASMIN; DIHYDROXYPHENYLALANINE; END STAGE LIVER DISEASE; HEPATITIS B; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LIVER CIRRHOSIS, ALCOHOLIC; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; RADIOPHARMACEUTICALS;

EID: 84858595211     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.771     Document Type: Article

References (12)

1. Rodier J. Manganese poisoning in Moroccan miners. Br J Ind Med. 1955;12(1): 21-35.
2. Spahr L, Butterworth RF, Fontaine S, et al. Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology. 1996;24(5):1116-1120. (Pubitemid 26365913)
3. Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology. 2005;64(12):2021-2028. (Pubitemid 40883102)
4. Yee RE, Irwin I, Milonas C, et al. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord. 2001;16(5):838-848. (Pubitemid 36041185)
5. Racette BA, Antenor JA, McGee-Minnich L, et al. [18F]FDOPA PET and clinical features in parkinsonism due to manganism. Mov Disord. 2005;20(4):492-496. (Pubitemid 40779027)
6. 18F]FDOPA PET in asymptomatic welders with occupational manganese exposure. Neurology. 2011;76(15):1296-1301.
7. Fahn S, Elton RL; Members of UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. New York, NY: Macmillan; 1987: 153-163.
8. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48(8):314-318. (Pubitemid 17138128)
9. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-470. (Pubitemid 32119037)
10. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33-39. (Pubitemid 29046907)
11. Heiss WD, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol. 2004; 11(1):5-12. (Pubitemid 38174915)
12. Wolters EC, Huang CC, Clark C, et al. Positron emission tomography in manganese intoxication. Ann Neurol. 1989;26(5):647-651.